WUHAN, China — Wuhan Keqian Biology Co., Ltd. (SHA: 688526) announced that its proprietary Feline Trivalent Inactivated Vaccine (protecting against Feline Viral Rhinotracheitis, Feline Calicivirus, and Feline Panleukopenia) has officially received the New Veterinary Drug Registration Certificate from China’s Ministry of Agriculture and Rural Affairs.
1. Domestic Strains Designed for Local Pathogen Profiles
Developed through a joint research alliance led by Keqian Biological in partnership with Huazhong Agricultural University, Yunnan Biological, and Huate Biotechnology, the newly registered biological product replaces imported reference viral strains with local isolates:
-
Targeted Strain Selection: The inactivated formulation utilizes three indigenous Chinese viral strains—WH-2017, LZ-2016, and CS-2016. These isolates specifically match the active antigenic variations and circulating field mutations observed across feline populations in domestic urban centers.
-
Immunity & Dosing Protocol: Clinical safety and challenge trials confirmed that a baseline two-dose primary immunization series confers a 12-month period of protective immunity, meeting national biosecurity standards for core feline vaccines.
In recognition of the vaccine’s technological breakthrough and indigenous innovation, regulators granted Keqian Biological a 3-year market exclusivity period.
2. Breaking the Monopoly: Disruption of Domestic Market Dependence
China’s companion animal vaccine sector has historically faced a structural supply deficit, with international pharmaceutical conglomerates controlling approximately 80% of the domestic market share for feline core vaccines.
The approval provides Chinese veterinary clinics with a price-competitive domestic alternative, mitigating vulnerability to import supply chain disruptions and addressing the growing demand driven by China’s expanding pet ownership demographic.
3. Strategic Expansion of Keqian’s Companion Animal Pipeline
The approval of the feline trivalent vaccine strengthens Keqian Biological’s broader strategy to expand beyond its traditional livestock biologicals business into high-margin companion animal therapeutics:
